This bitesize is one of a series showing data for Oxfordshire related to the cost of living, and is focused on the cost of renting.
ONS survey data for March 2022 shows a greater percentage of renters (37%) were finding it “very difficult” or “difficult” to pay usual household bills compared with a year ago than mortgagors (23%).
Ensuring every child has the best start in life is one the key priorities of the Office for Health Improvement and Disparities (OHID, formerly a part of Public Health England).
Investing in children and families and enabling children to thrive is a crucial part of achieving the Governments ‘Levelling Up’ agenda to reduce inequalities seen across the country. Delays in identifying and meeting the health and wellbeing needs of children and young people can have far reaching effects, impacting their chance of reaching their full potential and leading happy, healthy adult lives.
This Health Needs Assessment of school aged children (aged 5-19 years) has been carried out to gain a clearer picture of the needs of children, young people and their families across Oxfordshire. This will help to inform the delivery of the Healthy Child Programme, as part of the Local Authority’s responsibility to commission public health services for children.
The Pharmaceutical Needs Assessment (PNA) is a statutory report that is required to be produced by each local Health and Well Being Board (HWB) every three years or more frequently. The PNA is the means by which the community pharmaceutical services in a Health and Well Being Board area are reviewed and evaluations are made as to whether or not these services are adequately meeting the needs of the population.
The PNA should inform the commissioning of essential, enhanced and advanced services from community pharmacies by NHS England, and the commissioning of services from pharmacies by the Public Health department of the local authority and by other local commissioners such as the Clinical Commissioning Group (CCG). Moreover, NHS England has the responsibility for using PNAs as the basis for determining ‘market-entry’ to the local pharmaceutical list.
